Sheba Medical Center in Israel has become the first hospital outside the United States to adopt OpenAI's enterprise healthcare platform, extending a push that began with U.S. partners like Boston Children's Hospital, which reports reclaiming about 60,000 work hours through AI-enabled workflows.
A nationwide German study of nearly 500,000 women found AI-assisted mammogram reading increased breast cancer detection by about 17.6% without raising false positives, offering some of the strongest real-world evidence yet for AI's role in cancer screening.
An analysis of FDA regulatory data shows the agency has now cleared 1,614 AI-enabled medical devices, with radiology alone accounting for roughly 76% of the list and 2026 on pace to set a new annual record for clearances.
A study in NEJM AI from Boston Children's Hospital's Manton Center and OpenAI found that the o3 model helped identify 18 new diagnoses among 376 previously unsolved rare-disease cases, including a 15-years-overdue diagnosis for one patient, while researchers caution the tool requires careful human oversight.
Recursion Pharmaceuticals says its AI platform designed REC-7735, a selective PI3Kα-mutant cancer inhibitor, from 242 candidate compounds to a cleared IND in 10 months; the drug is headed into a Phase 1/2 trial as the company leans on partnerships with Roche's Genentech and Sanofi.
Insilico Medicine's rentosertib, an AI-designed drug for pulmonary fibrosis, entered Phase 3 trials on July 7, and the company's ISM6331 won FDA Fast Track designation for mesothelioma three weeks later — real progress in a field where no AI-discovered drug has yet won full approval.
Isomorphic Labs, the Google DeepMind spinout behind AlphaFold's drug-design successor, is reportedly in talks to raise funding at a valuation of $40 billion or more — before it has dosed a single patient in a clinical trial, which it says will begin by the end of 2026.
GSK becomes the sixth pharma partner to sign with AI protein-design startup Chai Discovery in nine months, part of a wave of deals pairing computational biologics design with traditional wet-lab drug development.
Bloomberg reports Alphabet's AI drug discovery unit is in early talks to raise at double its prior valuation, even as Demis Hassabis pushes back his timeline for the company's first human clinical trial to the end of 2026.
Tempus AI has expanded its collaboration with Merck and Moderna to help commercialize intismeran autogene, a personalized mRNA cancer vaccine built from each patient's tumor sequencing, as Tempus moves to acquire Personalis for its genomic profiling technology.